The microbiome therapeutics market is successfully commercializing Seres Therapeutics' SER-109 and Rebiotix's RBX-2660 for recurrent Clostridium difficile infection (Recurrent C. difficile).
While integrated omics-based projects are underway, researchers focus more on differences in gut microbiota between individuals that may be associated with disease expression. Still, they have yet to identify concrete biomarkers. While integrated omics analysis relies on correlation coefficients and algorithms, researchers are employing several omics approaches, and research is shifting from specific strains to multi-strain consortia.
This report covers the efforts of companies involved in the microbiome market. Also, it covers a wide range of topics, including market size, technology trends, applications in sequencing, health food, agriculture, livestock, skincare, industrial processes, regulations, and marketing. Trends in the global microbiome market are also summarized by country (and some areas), and the current market size, competitive landscape, and challenges are analyzed and forecasted for the future.
Countries Covered
- United States
- Canada
- Germany
- France
- United Kingdom
- China
- Japan
- India
- Others
Table of Contents
Chapter 1. Microbiome Market Trends
Chapter 2. Analysis by Microbiome application
Chapter 3. Trend Analysis by Company
Chapter 6. Conclusion
Companies Mentioned
- BGI
- Chr. Hansen
- DuPont
- Enterome
- Evelo Biosciences
- Gallinée
- Illumina
- L'Oréal
- Morinaga
- Nestle
- Probi
- Rebiotix
- Seres Therapeutics
- Vedanta Biosciences
- Yakult Honsha
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 69 |
| Published | November 2023 |
| Forecast Period | 2022 - 2027 |
| Estimated Market Value ( USD | $ 71.55 Billion |
| Forecasted Market Value ( USD | $ 120.56 Billion |
| Compound Annual Growth Rate | 11.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
